ATP6V1B1

Across TCGA pan-cancer cohorts, ATP6V1B1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATP6V1B1 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ATP6V1B1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ATP6V1B1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where ATP6V1B1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.231	0.937	.010	15	view →
HNSC	OS	Median	IV	0.809	0.484	.008	7	view →
CCRCC	DFS	Tertile	III,IV	0.733	0.395	.020	3	view →
LUAD	OS	Median	All	0.850	0.678	.045	2	view →
LSCC	DFS	Quartile	All	0.388	0.815	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATP6V1B1–PDAC (OS)

Open the PDAC breakdown →